Nasdaq

Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses

Danon Disease is a rare X-linked inherited disorder caused by mutations in the gene encoding lysosome-associated membrane protein 2 (LAMP-2), an important mediator of autophagy. This results in ...
Nasdaq

Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood ...
Seeking Alpha

Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead?

Rocket Pharmaceuticals announced yesterday it had reached agreement with the FDA on a potentially pivotal study of in vivo gene therapy candidate RP-A501. The drug candidate has faced a long journey ...
streetinsider

Rocket Pharmaceuticals (RCKT) Announces Presentations Highlighting Lentiviral Gene Therapies

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated ...